R. Hurst et al., Brain metastasis after immunotherapy in patients with metastatic melanoma or renal cell cancer: Is craniotomy indicated?, J IMMUNOTH, 22(4), 1999, pp. 356-362
The purpose of this study was to evaluate the outcome of surgical treatment
of brain metastasis in patients with metastatic melanoma or renal cell can
cer after interleukin-2 (IL-2) therapy. A retrospective analysis was conduc
ted at the Surgery Branch, National Cancer Institute. All patients with a d
iagnosis of metastatic melanoma or renal cell cancer who received IL-2 from
January 1, 1985 to January 1, 1996 (n = 1385) were screened for the develo
pment of brain metastasis, Forty patients underwent surgical treatment of b
rain metastasis that developed after initiating IL-2 therapy. Thirty-six we
re rendered free of disease after resection of a single metastasis and were
the focus of this study. Twenty-two of the 36 patients achieved a clinical
response (10 complete responses and 12 partial responses) at extracranial
sites of disease after IL-2-based immunotherapy and before the development
of brain metastasis. The median disease-free interval in the brain after re
section of a single metastasis was 21, 7, and 3 months for patients achievi
ng a complete response, pal tial response, and no response (CR, PR, and NR)
to IL-2 therapy, respectively. The median survival after craniotomy for th
ese three groups of patients was 23, 17, and 7 months, respectively. The di
sease-free interval in the brain and the overall survival after craniotomy
were significantly longer for patients achieving a CR to previous immunothe
rapy when compared with patients achieving a PR or NR. Of the 10 patients w
ho had achieved a prior CR, 8 remained disease free in the brain at last fo
llow-up, 6 remained alive beyond 1 year, and 3 >4 years. Twenty-five patien
ts experienced neurologic symptoms before craniotomy and all had complete r
esolution of their symptoms after surgery. Surgical treatment of single bra
in metastasis in patients with metastatic melanoma or renal cell cancer is
indicated in carefully selected patients. The benefits of resection include
palliation of symptoms and the potential for a prolonged disease-free inte
rval in the brain.